| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4932027 | Journal of Psychiatric Research | 2017 | 27 Pages |
Abstract
The pattern of results suggests that adjuvant buprenorphine augmentation can reduce symptoms of obsessive-compulsive disorders after only three weeks, compared to a placebo. Adjuvant buprenorphine seems to accelerate symptom improvement.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Mohammad Ahmadpanah, Amin Reihani, Ali Ghaleiha, Alireza Soltanian, Mohammad Haghighi, Leila Jahangard, Dena Sadeghi Bahmani, Edith Holsboer-Trachsler, Serge Brand,